Ninth Canadian Jurisdiction Implements Biosimilar Switching Policy

Newfoundland And Labrador Will Transition Patients To Biosimilars By The End Of March 2024

 
• By Chloe Kent
  
Newfoundland and Labrador on globe
Switching policy will allow province to invest in new innovative drug therapies and expand access to existing treatments • Source: Shutterstock

More from Biosimilars

More from Products